Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Immix Biopharma, Inc.NASDAQ: IMMX

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns negative

Q1 FY2026 change in working capital was -$470.34K, compared with $1.93M a year earlier. Trailing-twelve-month change in working capital was $301.74K. Over 3 fiscal years it compounded at +140.1% a year.

Context

  • Change in working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near -$470.34K or moves back toward the trailing-twelve-month quarterly average of $75.44K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$470.34K-53.1% QoQ
Last fiscal yearDec 2025
$2.7M-31.9% YoY
LTMMar 2026
$301.74K-94.4% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-124.4%——
1 year-31.9%——
3-year CAGR+140.1%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
2.7M USD
Year-over-year change
-31.9%

Change in Working Capital vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -94.4% is the 9th highest of 10, against a peer median of +58.8%.
  • Over three fiscal years its annual growth of +140.1% compares with a peer median of +24.6%.
IMMX Competitors
Change in Working Capital for IMMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$87M USD-18.7%—74.4%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$50.82M USD+271.7%+18.4%7.2%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥49.9M CNY—-68.6%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$29.7M USD-77.6%+30.8%83.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$20.49M USD+58.8%—18293.8%
MGNXMacroGenics, Inc.LTM Mar 2026$17.87M USD+67.2%+66.6%11.4%
IMUXImmunic, Inc.LTM Mar 2026$10.92M USD+78.7%-42.2%—
IMMPImmutep LimitedFY2025A$8.54M AUD-347.1%+76.2%169.4%
ABVXAbivax S.A.FY2025€3.51M EUR+146.5%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$994K USD-13.9%—189.3%
IMMXImmix Biopharma, Inc.LTM Mar 2026$301.74K USD-94.4%+140.1%—
Peer median (excluding IMMX) —+58.8%+24.6%83.6%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.38M)(8.23M)(15.6M)(21.61M)(29.44M)
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
Deferred Income Tax00000
Stock-Based Compensation218.98K624.07K2.57M3.02M2.44M
Change in Working Capital(391.04K)195.21K1.65M3.97M2.7M
Accounts Receivables97.67K(236.38K)(893.4K)(971.53K)2.06M
Inventory00000
Accounts Payables(106.06K)1.13M2.43M4.4M1.03M
Other Working Capital(382.64K)(700.15K)111.84K537.2K(384.74K)
Other Non-Cash Items22.96M002.94M0
Operating Cash Flow(1.59M)(7.41M)(11.37M)(14.6M)(23.93M)
Capital Expenditures(802)3(52.09K)(1.18M)(732.93K)
Acquisitions (Net)00000
Purchases of Investments0000(6.48M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(802)0(52.09K)(1.18M)(7.21M)
Debt Repayment200K(50K)000
Common Stock Issued18.65M3.39M15.7M15.95M107.39M
Common Stock Repurchased0(99.96K)000
Dividends Paid00000
Other Financing Activities0(6.72K)(232K)00
Financing Cash Flow18.85M3.23M15.46M15.95M107.39M
Effect of Forex Changes(5.43K)(31.52K)33.09K(3.62K)3.84K
Net Change in Cash17.25M(4.21M)4.07M172.16K76.25M
Free Cash Flow(1.59M)(7.41M)(11.42M)(15.77M)(24.66M)

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.